William Bergman Article Examines Calls for COVID IP Waivers

Articles / May 13, 2021

Partner William Bergmann authored an “Expert Analysis” published on May 13, 2021, by Law360. The article “COVID IP Waiver Doesn’t Resolve Vaccine Production Barriers” examines proposed waivers for some intellectual property protections related to COVID-19 treatments, including vaccines.

Bergmann’s article explores the ramifications of such waivers, examines how they might be implemented, and notes that the “know-how needed to develop vaccines and the accompanying infrastructure are much bigger barriers to their production” than the proprietary platforms that allowed the vaccine development.

He concludes that “there is a significant chance that the current global supply will exceed the demand for doses long before any developing countries actually begin production.”

Read the article (registration required).

Related Services

Related Emerging Issues